These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9087300)

  • 1. [Clinical evaluation of ondansetron suppository].
    Kobayashi F; Yamanouchi T; Shimizu T; Sato H; Adachi I; Sakamoto T; Fujimaki M; Horikoshi I
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):625-7. PubMed ID: 9087300
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
    Zhou J; Xu B; Zhou A
    Zhonghua Zhong Liu Za Zhi; 1997 Nov; 19(6):460-2. PubMed ID: 10920884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting].
    Gershanovich ML; Beresneva IA; Makhnova EV
    Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
    Ishida T; Kusaba T; Hayakawa H
    Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ondansetron: a useful addition to the supportive care armamentarium?
    Hesketh PJ
    Am J Clin Oncol; 1994 Apr; 17(2):147-9. PubMed ID: 8141106
    [No Abstract]   [Full Text] [Related]  

  • 10. Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study.
    Shi Y; He X; Yang S; Ai B; Zhang C; Huang D; Dong M; Liu P; Zhou S; Han X
    Chemotherapy; 2007; 53(1):44-50. PubMed ID: 17202811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Ahn JH; Kang YK; Kim TW; Bahng H; Chang HM; Kang WC; Kim WK; Lee JS; Park JS
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):104-10. PubMed ID: 12172973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
    Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
    Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
    Kim K; Chie EK; Jang JY; Kim SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
    Jpn J Clin Oncol; 2009 Feb; 39(2):111-5. PubMed ID: 19060294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
    Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
    J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ondansetron in the control of emesis in autologous peripheral blood stem cell transplant (APBSCT) for solid tumours.
    Leong SS; Teo CP; Tao M; Ang PT
    Singapore Med J; 1998 Sep; 39(9):396-8. PubMed ID: 9885717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.